For the first time, it is confirmed that malaria atorvavir resistance cannot be transmitted by mosquitoes. April 21, 2016 Source: Bio Valley
Supply factory price Veterinary drugs,Tilmicosin Powder Price,Ampicillin FActory Price,Tylosin Tartrate Activity,Monensin Powder for Sale,
China Veterinary raw,Low Price Ampicillin supplier & manufacturer, offer low price, high quality Cas 7177-48-2 Ampicillin,Ampicillin Powder, etc.
Veterinary drugs,Tilmicosin Powder Price,Ampicillin FActory Price,Tylosin Tartrate Activity,Monensin Powder for Sale Xi'an Henrikang Biotech Co.,Ltd , https://www.xianhenrikang.com
Now we have 3 GMP standard workshop, Meanwhile, the factory is equipped with the researching and quality inspection centre, with strong technology research and development strength. We also have 3 salesdepartments over 30 people and sell our products all over the world.
For customer`s needs, OEM service is also acceptable. If you have a good idea in new product production but lack of laboratory device and human resource, we are glad to solve this problem for you. Sincerely hope to strengthen exchanges and cooperation with friends from both home and abroad.
For the first time, it is confirmed that malaria atorvavir resistance cannot be transmitted by mosquitoes.
In a new groundbreaking study, researchers from institutions such as the University of Melbourne in Australia found that resistance to a vital anti-malarial drug could not be transmitted by mosquitoes. This finding may significantly improve our approach to malaria. The results of the study were published in the April 15th issue of Science , entitled "Parasites resistant to the antimalarial atovaquone fail to transmit by mosquitoes".
Â
This finding may potentially prevent malaria resistance through large-scale transmission of mosquitoes, making malaria treatment more effective for 3.2 billion people at risk.
Â
The study focused on the drug atovaquone. In 2000, atovaquone was marketed and safe for pregnant women and children. Therefore, it is one of the few antimalarial drugs that can be used in large-scale administration methods. However, it has been largely eliminated because it began to observe the resistance of the malaria parasite to this drug.
Â
But in this new study, the researchers revealed that although some Plasmodium mutated in the cytochrome b gene to allow them to resist the drug early in life, when they parasitized in mosquitoes, the mutation prevented one. The necessary types of energy are produced and eventually kill them.
Â
The main authors of the paper, Professor Geoff McFadden and Dr. Dean Goodman, call this mutation a "genetic trap," which may prove to be a big step in the fight against malaria.
Â
The two authors and longtime collaborator Vanessa Mollard led an international research team to study the evolution and life cycle of the malaria parasite in six years.
Â
Professor McFadden from the University of Melbourne's College of Biological Sciences said, "These results are very exciting because the spread of resistance is currently undermining our ability to control malaria."
Â
“We now understand this specific genetic mutation that causes some Plasmodium populations to develop resistance and how this mutation ultimately kills them in mosquitoes, thus providing new targets for the development of drugs.â€
Â
"So if drug resistance does not spread, this resistance may not be a big problem, which means that the drug atovaquone may be more widely used in malaria control."
Â
The team also includes colleagues from the Eijkman Institute and Hasanuddin University in Indonesia, colleagues from the Japanese Autonomous Medical University, Nagasaki University and the University of Tokyo, and John Hopkin from the United States. Colleague of the University.
Â
The researchers studied a rodent Plasmodium model strain and a deadly human Plasmodium falciparum strain, confirming that the atovaquone-resistant Plasmodium cannot be transmitted by mosquitoes, thus preventing their re-humanization. infection.
Â
“This is very worthwhile: our persistent research on basic biology has achieved these remarkable results.â€
Â
“We are the first research team to track the entire life cycle of Atorvamycin-resistant Plasmodium to understand what happens after drug resistance is initially produced and whether they will spread this resistance.â€
Â
“Our next challenge will be to find out whether this resistance is spreading in the on-site environment in countries such as Kenya and Zambia. We hope that with the development of the cheap generic drug Atopurine, people will be treating malaria. There are new hopes in it."